Key result
PNA staining increases ~5-fold in GNEM muscle, emerging as a promising biomarker for sialylation restoration.
Why the study?
Robust molecular biomarkers of sialic acid deficiency and therapeutic restoration in GNE myopathy are lacking, limiting early assessment of gene therapy response.
Can glycan-binding lectins serve as robust biomarkers of sialic acid deficiency and restoration in GNE myopathy?
Can glycan-binding lectins serve as robust biomarkers of sialic acid deficiency and restoration in GNE myopathy?
The glycan-binding lectin PNA demonstrates robust performance as a biomarker for sialylation restoration, showing promise for assessing gene therapy response in GNE myopathy.
Answers are grounded in this paper and cite their sources.
PNA may mark sialic acid deficiency and restoration in GNE myopathy; hypothesis-generating for gene therapy response monitoring.
INTRODUCTION/AIMS: GNE myopathy (GNEM) is a rare, autosomal recessive disorder caused by mutations in the UDP-N-acetylglucosamine (GlcNAc) 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE) gene, which encodes a required enzyme for sialic acid (SA) biosynthesis. Reduced SA production is associated with progressive skeletal muscle wasting, but robust molecular biomarkers of SA deficiency and therapeutic restoration remain lacking. As gene therapy for GNEM continues to advance, there is a critical need for biomarkers that enable early, objective assessment of therapeutic response that may precede detectable clinical improvements. Here, we systematically compare a panel of glycan-binding lectins to identify sensitive and robust biomarkers of SA deficiency and restoration in GNEM. METHODS: We evaluated a panel of glycan-binding lectins for differential binding under altered sialylation using fluorescent staining and flow cytometry in a GNE-deficient cell model, followed by fluorescent lectin staining of skeletal muscle biopsies from GNEM and non-GNEM patients. RESULTS: Subterminal lectins SBA, PNA, and VVA showed greater sensitivity to hyposialylation than terminal lectins. By flow cytometry, SBA and PNA increased 90.38- and 50.03-fold, respectively, in GNE-deficient cells and decreased 96.06% and 91.83% following GNE restoration. In GNEM muscle, PNA showed the greatest increase (5.3-fold) and most consistent discrimination from non-GNEM muscle. DISCUSSION: PNA demonstrated the most robust and consistent performance across models, supporting its promise as a biomarker to reflect restoration of sialylation that would occur in skeletal muscle after GNEM gene therapy. Further validation in clinical samples will establish its utility as a pharmacodynamic biomarker.
No takes yet. Share an insight, caveat, or question.
Sattler et al. (2026) studied GNE myopathy (GNEM). Glycan-binding lectins (e.g., PNA, SBA) vs. Non-GNEM muscle and GNE-restored cells was evaluated on Differential binding under altered sialylation. PNA staining increased 5.3-fold in GNEM muscle compared to non-GNEM muscle, demonstrating its promise as a robust biomarker for sialylation restoration in GNE myopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: